Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Galderma Group AG (GALD)
Galderma Group AG stock price live, this page displays SIX GALD stock exchange data. View the GALD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Galderma Group AG real time stock price chart below.
What Is the Galderma Group AG Stock Price Today?
The Galderma Group AG stock price today is 132.00.
What Is the Stock Symbol for Galderma Group AG?
The stock symbol for Galderma Group AG is ""GALD.""
What Stock Exchange Does Galderma Group AG Trade On?
Galderma Group AG is listed and trades on the Switzerland stock exchange.
Is Galderma Group AG a Good Stock to Buy?
Determining whether Galderma Group AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GALD quote. (ISIN: CH1335392721)
What Is the Galderma Group AG Stock Price Today?
The Galderma Group AG stock price today is 132.00.
What Is the Stock Symbol for Galderma Group AG?
The stock symbol for Galderma Group AG is ""GALD.""
What Stock Exchange Does Galderma Group AG Trade On?
Galderma Group AG is listed and trades on the Switzerland stock exchange.
Is Galderma Group AG a Good Stock to Buy?
Determining whether Galderma Group AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GALD quote. (ISIN: CH1335392721)
132.00
+1.00(+0.76%)
Closed·
Fair Value
An estimate of a Galderma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
131.70
133.30
52 wk Range
72.70
138.80
GALD Scorecard
Full Analysis
Net income is expected to grow this year
GALD is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a Galderma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
131.70133.30
52 wk Range
72.70138.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GALD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Galderma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
137.22
Upside
+3.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Galderma Group AG Company Profile
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Galderma Group AG Earnings Call Summary for Q1/2025
- Q1 2025 net sales hit record $1.129B, up 8.3% YoY; stock surged 12.1% post-earnings
- Injectable aesthetics ($547M, +9.9% YoY) and neuromodulators ($311M, +21.4% YoY) drove growth
- Full-year guidance reaffirmed: 10-12% net sales growth, core EBITDA margin ~23%
- New product launches, international expansion key growth drivers; China and Asia-Pacific focus
- EPS expected to reach $2.74 in FY2025; company confident despite potential US tariff impacts
Last Updated: 24/04/2025, 16:00
Read Full TranscriptCompare GALD to Peers and Sector
Metrics to compare | GALD | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipGALDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 102.8x | −1.6x | −0.6x | |
PEG Ratio | 0.04 | 0.00 | 0.00 | |
Price/Book | 5.0x | 2.0x | 2.6x | |
Price / LTM Sales | 8.3x | 1.6x | 3.3x | |
Upside (Analyst Target) | 6.1% | 32.9% | 40.2% | |
Fair Value Upside | Unlock | 2.8% | 5.1% | Unlock |
Analyst Ratings
8 Buy
3 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 137.22
(+3.95% Upside)
Earnings
Latest Release
Jul 24, 2025
EPS / Forecast
0.82 / --
Revenue / Forecast
2.47B / 1.098B
People Also Watch
FAQ
What Stock Exchange Does Galderma Trade On?
Galderma is listed and trades on the Switzerland Stock Exchange stock exchange.
What Is the Stock Symbol for Galderma?
The stock symbol for Galderma is "GALD."
What Is the Galderma Market Cap?
As of today, Galderma market cap is 31.34B.
What Is Galderma's Earnings Per Share (TTM)?
The Galderma EPS (TTM) is 1.59.
From a Technical Analysis Perspective, Is GALD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Galderma Stock Split?
Galderma has split 0 times.
How Many Employees Does Galderma Have?
Galderma has 0 employees.
What is the current trading status of Galderma (GALD)?
As of 18 Aug 2025, Galderma (GALD) is trading at a price of 132.00, with a previous close of 131.00. The stock has fluctuated within a day range of 131.70 to 133.30, while its 52-week range spans from 72.70 to 138.80.
What Is Galderma (GALD) Price Target According to Analysts?
The average 12-month price target for Galderma is CHF137.21794355, with a high estimate of CHF164.77580645 and a low estimate of CHF93.55806452. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.95% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.